Navigation Links
Study raises questions about prostate cancer therapies targeting IGF-1
Date:4/30/2008

SEATTLE Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene p53 is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

IGF-1 is a polypeptide hormone that can influence growth, differentiation and survival of cells expressing the type 1 receptor (IGF-1R). Past clinical, epidemiological and experimental studies have strongly implicated IGF-1 as a contributing factor in the natural history of prostate cancer. However, very little has been done to prove absolutely that the expression or activation of the IGF-1 signaling pathway at physiologically relevant levels is sufficient to cause a healthy prostate cell to become a cancer cell.

Norman Greenberg, Ph.D., and colleagues conducted a pair of experiments by manipulating gene expression directly in the epithelial compartment of the mouse prostate gland to better understand the role of IGF-1R. In contrast to studies that correlated elevated levels of IGF-1 with the risk of developing prostate cancer, Greenbergs research showed that eliminating IGF-1R expression in an otherwise normal mouse prostate caused the cells to proliferate and become hyperplastic. Although persistent loss of IGF-1R expression ultimately induced cell stasis and death, both of these processes are regulated by the tumor suppressor gene p53 that is commonly mutated in human prostate cancers. Hence the researchers hypothesized that tumors with compromised p53 might not respond predictably to therapies targeting IGF1 signaling.

To test their reasoning they conducted a second experiment by crossing mice carrying the prostate-specific IGF-1R knockout alleles with transgenic mice that develop spontaneous prostate cancer when p53 and select other genes are compromised. The results were as predicted: Prostate epithelial-specific deletion of IGF-1R facilitated the emergence of aggressive prostate cancer in the genetically-engineered tumor prone mice.

Published in the May 1 edition of Cancer Research, the study supports a critical role for IGF-1R signaling in prostate tumor development and identifies an important IGF-1R-dependent growth control mechanism, according to the authors. Title of the paper is Conditional deletion of insulin-like growth factor-1 receptor in prostate epithelium.

If our predictions hold true, tumor cells with intact p53 may show the best response to therapy targeting the IGF-1R signal, however when p53 is not functioning normally, response to this therapy may not be as expected, said Greenberg, the studys corresponding author and a member of the Hutchinson Centers Clinical Research Division.

Greenbergs message to clinicians who administer IGF-R1 therapy: Were all hoping for good results but lets proceed with caution.

A search of the database for clinical trials registered with the National Cancer Institute found 18 trials in process that use therapies to inhibit IGF-R1. None of them include a tumors p53 status as a criterion for recruiting research participants, said Greenberg.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Children More Vulnerable to Harmful Effects of Lead at Age 6 Than as Toddlers, Says New Study
2. Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers
3. Penn study finds elderly heart patients with ICD devices live longer after heart failure
4. Physical activity, healthy eating and BMI not linked in older teens: study
5. Salk study links diabetes and Alzheimers disease
6. U of M study: Online intervention paramount for reducing HIV in high-risk population
7. Study Reveals Women Feeling Growing Financial Pressures on Family Life
8. Experimental Blood Substitutes Unsafe, Study Finds
9. Spinal cord injury research hampered by animal models, says new study
10. Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted
11. Kaiser Permanente study finds diabetes doubling before motherhood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and staff members in 2017 who are passionate about making a difference in ... 1994 and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
(Date:1/19/2017)... ... , ... Sam & Associates Insurance Agency, a full service firm providing asset ... Bay Area, is launching a charity drive to raise awareness of heart disease risk ... primary killer of adult men and women in America, and is responsible for over ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, a ... throughout eastern Georgia, is embarking on a charity effort to raise awareness and ... Americans every year than anything else, yet risk factors associated with heart disease ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
(Date:1/19/2017)... 2017 Accuray Incorporated (Nasdaq: ARAY ... continue to set the bar for excellence in customer ... user satisfaction rating among radiation treatment delivery systems in ... Market Intelligence Briefing™. The most recent ratings trend also ... industry peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology: